HHighlight Therapeutics — Series A (estimated) · €9M
In a September 2019 interview, the CEO said Bioncotech Therapeutics (now Highlight Therapeutics) closed a €9M bridge round in May 2019. Investors were not named, but the company's venture backers at the time were Advent (UK), Droysen (Belgium) and Columbus (Spain). Earlier money came from Valencian family offices and business angels, with venture capital entering from 2015. CB Insights lists a 31 May 2019 debt round of undisclosed size.
Lead not disclosed
RoundSeries A (estimated)
AnnouncedMay 2019
CityValencia
SectorHealthtech & Bio · Biotech / Immuno-oncology
Source
E
E
The company
Investors
No investors were disclosed for this round.